Barclays (LON:BARC) analyst Carter Gould maintained a Hold rating on Biogen (NASDAQ:BIIB) on Wednesday, setting a price target of $280, which is approximately 25.04% above the present share price of $223.92.
Gould expects Biogen to post earnings per share (EPS) of $0.00 for the fourth quarter of 2021.
The current consensus among 22 TipRanks analysts is for a Moderate Buy rating of shares in Biogen, with an average price target of $354.75.
The analysts price targets range from a high of $502 to a low of $259.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $2.78 billion and a net profit of $778.4 million. The company's market cap is $32.89 billion.
According to TipRanks.com, Barclays analyst Carter Gould is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.6% and a 42.35% success rate.
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.